ArticleRespiratory medicine case reports2026
Lung cancer in patients with scleroderma-associated interstitial lung disease: Case series and implications for screening.
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with scleroderma associated interstitial lung disease (SSc-ILD) are at an increased risk for lung cancer, necessitating a high index of suspicion for timely detection. This case series describes three patients with SSc-ILD who developed lung cancer, highlighting diagnostic and therapeutic challenges in detecting and managing malignancy within abnormal lung parenchyma. Methods: Electronic medical records were reviewed by a team of physicians. Clinical, radiographic, and pathologic data from each patient's disease course were synthesized to illustrate diagnostic workup and management decisions. Results: The series includes two former smokers with minimal smoking history and one never-smoker. Lung cancer stages at diagnosis ranged from IA to IVb. Positron emission tomography imaging was instrumental in raising suspicion for malignancy and selecting diagnostic sites. Pausing immunosuppression led to ILD progression for all patients. Conclusion: This case series emphasizes the importance of maintaining a high index of suspicion for lung cancer in patients with SSc-ILD, including among minimal or non-smokers, and highlights the urgent need for future research into risk factors and mechanistic pathways, screening strategies, and management approaches for lung cancer in SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.